

# market announcement

For Public Release

NZX Limited Wellington

22 December 2023

### **Cannasouth Announces Director Resignations**

Cannasouth Limited (NZX: CBD, Cannasouth) announces that Mrs. Hilary Webber, Independent Non-executive Director, and Mr. Greg Misson, Executive Director, of Cannasouth will step down from their positions with the company effective 1 January and 5 January 2024 respectively. Mr. Misson will continue in his executive management role to 31 March 2024.

Mr. Tony Ho, chairman, thanks Mrs. Webber and Mr. Misson for their service on the Cannasouth Ltd board since the merger with Eqalis Group New Zealand Ltd (Eqalis) on 1 June 2023, and acknowledges the significant contribution to the affairs of Eqalis over their respective terms.

"On behalf of the board, we thank Mrs. Webber and Mr. Misson for their contributions to the successful merger of Egalis and Cannasouth, and for their ongoing interest in Cannasouth."

The board intends to appoint a new Australian based director as part of the planned ASX dual listing in 2024.

Mr. Ho will replace Mrs. Webber on the Audit and Finance Committee as an Independent Non-executive director from 1 January 2024.

-ENDS-

For further information visit <a href="https://www.cannasouth.co.nz">www.cannasouth.co.nz</a> or contact:

## **Tony Ho**

Chairman, Cannasouth Limited Email: <a href="mailto:tony.ho@cannasouth.co.nz">tony.ho@cannasouth.co.nz</a>

Mobile: +61 (0)417 345 839

#### **Mark Lucas**

CEO / Executive Director Email: <u>mark.lucas@cannasouth.co.nz</u>

Mobile: 021 484 649

#### **About Cannasouth Limited**

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products are produced under GMP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd and Eqalis Group New Zealand Ltd.

For video footage, photos and logos please visit: <a href="https://www.cannasouth.co.nz/about/media/">https://www.cannasouth.co.nz/about/media/</a>